Alliance for Clinical Trials in Oncology

Alliance for Clinical Trials in Oncology Alliance develops and conducts cancer clinical trials as part of NCI National Clinical Trials Network

Follow us on Twitter!
- www.twitter.com/ALLIANCE_Org/

Alliance investigators will present two oral abstracts today at the 2026 ASCO Annual Meeting focused on improving outcom...
05/30/2026

Alliance investigators will present two oral abstracts today at the 2026 ASCO Annual Meeting focused on improving outcomes and quality of life for patients with advanced . Atish Choudhury, MD, PhD, will present findings from A-DREAM (A032101), while Alicia Morgans, MD, MPH, will present results from ARACOG (AFT-47), a randomized study comparing the cognitive effects of darolutamide and enzalutamide.

Today at , Alliance investigators Jennifer Ligibel, MD (of Dana-Farber Cancer Institute) and Rana McKay, MD (of Univers...
05/29/2026

Today at , Alliance investigators Jennifer Ligibel, MD (of Dana-Farber Cancer Institute) and Rana McKay, MD (of University of California San Diego) present two important oral abstracts: A011401/BWEL trial examines the impact of weight loss intervention on quality of life and symptoms in women with , while the Alliance A031801/RADICAL trial evaluates radium-223 plus cabozantinib in renal cell carcinoma with bone metastases.

Alliance for Clinical Trials in Oncology and Alliance Foundation Trials to present a dynamic portfolio of research at ,...
05/29/2026

Alliance for Clinical Trials in Oncology and Alliance Foundation Trials to present a dynamic portfolio of research at , highlighting advances in precision oncology, biomarker discovery, survivorship, ctDNA, AI, and patient-centered cancer care across multiple disease areas. Our investigators look forward to sharing research that continues to advance the future of cancer care and clinical trials - https://bit.ly/AllianceAtASCO26

Dr. Anne Beaven of UNC Lineberger leads Alliance A052101, a clinical trial designed to answer an important question for ...
05/29/2026

Dr. Anne Beaven of UNC Lineberger leads Alliance A052101, a clinical trial designed to answer an important question for older adults with mantle cell lymphoma (MCL):
➡️ Can patients who achieve remission safely receive fewer treatments of the targeted therapy zanubrutinib—without compromising outcomes?
Zanubrutinib, a Bruton tyrosine kinase (BTK) inhibitor, has shown strong effectiveness in treating MCL. However, long-term continuous treatment can bring side effects, financial toxicity, and quality of life challenges, particularly for older adults. This study explores whether a reduced duration treatment approach could maintain disease control while lowering treatment burden.
Why this trial matters:
🔹 Could help older patients avoid unnecessary long-term therapy
🔹 May reduce cumulative toxicity and improve daily quality of life
🔹 Supports a more individualized, remission guided treatment strategy
🔹 Adds important evidence to optimize the use of BTK inhibitors in lymphoma care
Learn more about the study and its goals:
https://bit.ly/Alliance-A052101

For patients with early-stage triple-negative breast cancer who achieve a pathologic complete response after chemotherap...
05/28/2026

For patients with early-stage triple-negative breast cancer who achieve a pathologic complete response after chemotherapy and pembrolizumab, what’s next? Should treatment continue—or is monitoring enough?
The Alliance A012103 trial, led by Dr. Sara Tolaney at Dana-Farber, and is a phase III study designed to compare:
✅ Continuing pembrolizumab after surgery
✅ Monitoring only (“watch and wait”)
Why does this matter? If monitoring proves just as effective, patients could avoid unnecessary treatment, reduce side effects, and improve quality of life—while still maintaining excellent outcomes.
This research could reshape how we approach care for TNBC patients who respond well to initial therapy.
📌 Learn more or share with your network: https://bit.ly/Alliance-A012103

https://bit.ly/Alliance-A012103

🚨 Now Enrolling: A021901 / B LuRE Clinical Trial 🚨The B LuRE trial (A021901) study is now open for enrollment through th...
05/27/2026

🚨 Now Enrolling: A021901 / B LuRE Clinical Trial 🚨
The B LuRE trial (A021901) study is now open for enrollment through the Alliance for Clinical Trials in Oncology!
Led by Thomas Hope, MD of UCSF and Suki Padda, MD of Fox Chase Cancer Center, this important trial is evaluating a new treatment approach for patients with bronchial neuroendocrine tumors.
🔬 What the study is testing:
B LuRE is comparing a radioactive drug (a form of targeted radiopharmaceutical therapy) with standard chemotherapy to see which option offers better outcomes for people living with bronchial neuroendocrine tumors.
This trial has the potential to advance care for a rare and often difficult to treat disease by exploring therapies that can more precisely target cancer cells while sparing healthy tissue.
👉 Learn more about the study and eligibility here:
https://bit.ly/Alliance-A021901

Led by Adrienne Waks, MD, of the Dana Farber Cancer Institute, A012303 (ShortStop HER2), is Phase III clinical trial now...
05/26/2026

Led by Adrienne Waks, MD, of the Dana Farber Cancer Institute, A012303 (ShortStop HER2), is Phase III clinical trial now open for enrollment through the Alliance for Clinical Trials in Oncology.
👉 This study asks if people with early stage HER2 positive breast cancer who have no cancer left (pCR) after neoadjuvant chemotherapy + HER2 targeted therapy, can safely have less treatment after surgery?
Many patients who achieve a pathologic complete response still receive additional therapy after surgery, even though we know pCR is associated with excellent outcomes. ShortStop HER2 aims to determine whether a shorter, less intensive approach can maintain effectiveness while reducing treatment burden, side effects, and cost.
If successful, this study could be practice changing by offering patients:
• A more personalized treatment pathway
• Lower toxicity
• Improved quality of life
• Reduced overtreatment
🔬 Learn more or share the trial information here:
👉 https://bit.ly/Alliance-A012303

📢 Clinical trial now enrolling! Jennifer Ligibel, MD (Dana-Farber Cancer Institute) and Kathryn Schmitz, PhD (UPMC Hillm...
05/25/2026

📢 Clinical trial now enrolling! Jennifer Ligibel, MD (Dana-Farber Cancer Institute) and Kathryn Schmitz, PhD (UPMC Hillman Cancer Center) are leading Alliance A222302, a study exploring the feasibility of a telehealth exercise program for cancer patients. The goal? To help reduce fatigue and disability and improve quality of life. Learn more about the trial here: https://bit.ly/DEFEND-trial

Exciting work happening in the fight against advanced kidney cancer!Rana McKay, MD, of UCSD Health leads Alliance A03180...
05/22/2026

Exciting work happening in the fight against advanced kidney cancer!
Rana McKay, MD, of UCSD Health leads Alliance A031801 (RadiCaL), a clinical trial exploring whether adding the novel anti-cancer agent radium-223 dichloride to the standard therapy cabozantinib can improve outcomes for patients.
What are these treatments?
• Cabozantinib is a pill that helps slow cancer growth by blocking signals tumors use to spread.
• Radium-223 dichloride is a targeted radioactive medicine that goes to areas in the bone where cancer has spread, helping destroy cancer cells and reduce bone pain.
Together, this combination aims to improve survival, reduce bone complications, and enhance quality of life for patients. Learn more and see how you can get involved: http://bit.ly/AllianceA031801

🚨 Now Enrolling!Sascha Tuchman, MD, of UNC Lineberger leads Alliance A062102, a new study for people living with multipl...
05/21/2026

🚨 Now Enrolling!
Sascha Tuchman, MD, of UNC Lineberger leads Alliance A062102, a new study for people living with multiple myeloma. This trial is looking at whether a daily pill called iberdomide can help keep myeloma under control longer compared with the usual approach of simply monitoring the disease after initial treatment.
What the study is trying to learn:
➡️ Can iberdomide help people stay in remission longer?
➡️ Could it improve overall survival?
➡️ How does it compare to regular follow up without additional treatment?
Why this matters:
Multiple myeloma often comes back over time, even after successful treatment. Finding maintenance options that are effective and easy to take could make a meaningful difference for patients and families.
Alliance A062102 is now enrolling participants who want to help advance future care for myeloma.
Learn more about the study: https://bit.ly/Alliance-A062102

Now enrolling! The Alliance A032103 (GAIN) trial is a phase III study evaluating whether adding gemcitabine, a well-esta...
05/21/2026

Now enrolling! The Alliance A032103 (GAIN) trial is a phase III study evaluating whether adding gemcitabine, a well-established chemotherapeutic agent, to BCG can reduce recurrences in patients with NMIBC who have experienced recurrence after BCG.
Key objectives:
✔ Assess efficacy of BCG + gemcitabine vs BCG alone
✔ Determine impact on recurrence-free survival and progression
📌 Learn more: https://bit.ly/Alliance-GAIN-BCG

Address

Alliance For Clinical Trials In Oncology, Alliance Operations, 311 S. Wacker Drive, Suite 2650
Chicago, IL
60606

Opening Hours

Monday 9am - 5pm
Tuesday 9am - 5pm
Wednesday 9am - 5pm
Thursday 9am - 5pm
Friday 9am - 5pm

Telephone

+16177328919

Website

Alerts

Be the first to know and let us send you an email when Alliance for Clinical Trials in Oncology posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Category